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Abstract 
Congestive heart failure (CHF) is associated with increased stress and alterations in metabolism, 
favoring catabolism over anabolism. Hormonal profiles of patients with heart failure have been 
assessed using serum and saliva as matrices, which are only point measurements and do not 
provide long-term information. Scalp hair is a novel matrix that allows for measurement of 
hormones over a period of several months. We aimed to evaluate whether levels of cortisol and 
testosterone and their ratio (C/T) in hair correlate with severity of heart failure. We conducted a 
prospective study in ambulatory male patients with a left ventricular ejection fraction (LVEF) 
≤40%. Hormone levels were measured using immunoassays in the proximal 2 cm of hair 
(representing approximately two months of systemic hormone exposure). Primary endpoints 
included the correlation of hair cortisol, testosterone, and C/T levels with the New York Heart 
Association (NYHA) class, LVEF, exercise capacity and NT-proBNP. The 44 CHF patients had 
a median hair level (range) of cortisol of 207 (117.7-1277.3) ng/g. Hair cortisol levels correlated 
positively with NYHA class (r=0.48, p=0.001) and negatively with treadmill stress test 
performance, (r=-0.37, p<0.05). The hair testosterone was 5.17 (2.39-24.64) ng/g and the C/T 
ratio was 39.89 (12.98-173.73). No associations were found between hair testosterone and C/T 
ratio and heart failure severity; however, the C/T ratio was higher in patients who required a 
CHF-related hospitalization than in patients who did not require this in the year following the 
inclusion in the study. Hair cortisol levels correlate with heart failure severity as assessed by the 
NYHA class and exercise capacity, while hair testosterone and C/T levels do not correlate with 
heart failure severity. 
Keywords:  Cortisol, Hair analysis, Heart failure, Prognosis, Testosterone 
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CHAPTER 1:  INTRODUCTION 
1.1  Heart Failure 
 Heart failure is a progressive disease that occurs when the heart is unable to eject 
sufficient blood to meet the metabolic demands of the body.  There are approximately 500,000 
Canadians living with heart failure and 50,000 new patients are diagnosed each year (Ross et al. 
2006).  There are two main types of heart failure, systolic and diastolic heart failure. This thesis 
will focus on systolic heart failure (also referred to congestive heart failure in this thesis). 
Systolic heart failure (HF) is commonly caused by uncontrolled hypertension, myocardial 
infarction, and/or valve dysfunction, consequently leading to decreased cardiac output (CO). CO 
is the product of stroke volume (SV) and heart rate (HR). The body reacts to decreased CO by 
releasing renin into the circulation from the juxtaglomerular cells of the kidney and stimulating 
the sympathetic nervous system to increase HR.  Renin converts angiotensinogen to 
angiotensinogen I, which is subsequently converted to angiotensinogen II by angiotensin 
converting enzyme (ACE). Angiotensin II causes arterial and venous constriction increasing 
blood pressure. Angiotensin II and chronic high blood pressure causes cardiac remodelling 
where the cardiac myocytes hypertrophy, leading to decreased contractility of the heart and SV 
as well. Due to the decreased SV, the CO decreases further, more renin is released and a vicious 
cycle ensues. HF patients often have resting tachycardia in an attempt to compensate for 
decreased SV. Angiotensin II also stimulates the secretion of aldosterone from the adrenal cortex 
and endothelin from endothelial cells. Endothelin further contributes to the high blood pressure 
by constricting blood vessels. Aldosterone causes the distal tubules and collecting duct of the 
kidneys to reabsorb sodium and water, exacerbating the hypertension. Due to the chronic 
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retention of water and salt, edema occurs including in the lungs of systolic heart failure patients, 
which increases the strain on an already weak heart. Additionally, aldosterone and endothelin 
have been shown to contribute to the cardiac remodelling described above (Agapitov et al. 2002, 
Barr et al. 1995, Farquharson et al. 2000). The effect of cortisol and testosterone in heart failure 
are discussed in Chapter 2.  
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1.2  Prognostic markers of heart failure 
 Accurate classification of HF patients with respect to prognosis would potentially benefit 
from intensive medical therapy and/or cardiac transplantation is a major challenge. Currently, 
there are several clinical and laboratory predictors of survival including the New York Heart 
Association (NYHA) functional class, left ventricular ejection fraction (LVEF), exercise 
capacity, and N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) levels.  
1.2.1  New York Heart Association Class 
There are four classes in the NYHA criteria. Class I HF is associated with no limitation 
and symptoms while performing ordinary activities; however during exercise, limitations and 
symptoms become apparent. Class II HF is characterized by slight limitation on ordinary activity 
resulting in fatigue and palpitations. Class III HF patients have no symptoms at rest, but fatigue 
easily with less than normal daily activity. Class IV HF is associated with symptoms at rest and 
the inability to carry out any physical activity. A limitation of the NYHA score is that it is not 
very reproducible and does not reliably predict the exercise capacity (Raphael et al. 2007). 
1.2.2  Left Ventricle Ejection Fraction 
 LVEF is a measurement of the percentage of blood leaving the heart each time it 
contracts. LVEF can be measured by echocardiography or radionuclide angiography. 
Radionuclide angiography involves injection of a radioisotope into the blood to detect its flow 
through the left ventricle. Healthy individuals typically have ejection fractions between 50% and 
65% (Kumar et al. 2009). In HF patients, LVEF falls below 35 to 40 percent. Interestingly, there 
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is no predictable relationship between symptoms or exercise capacity and LVEF; however in 
general, lower LVEFs are associated with worse prognosis (Wong et al. 2004). 
1.2.3  Exercise capacity 
 Exercise capacity is reduced in patients with HF and has been shown to outperform 
traditional markers of heart failure prognosis (Myers et al. 2002, O’Connor et al. 2012). 
Treadmill stress test protocols such as the Bruce protocol and Naughton protocol can be used to 
assess exercise capacity.  The Bruce protocol is carried out by walking on a treadmill. The initial 
speed of the treadmill is set to 2.7 km/h and the incline is set to 10%. After every 3 minutes, the 
end of one stage, both the speed and inclination of the treadmill is increased.  The test is 
generally stopped when ECG machine shows abnormal changes or when a patient reaches his 
peak heart rate. Patients’ heart rates and perceived exertion are taken every minute. Blood 
pressure is taken at the end of each stage. The Naughton protocol is less intense compared to the 
Bruce protocol. It begins with a two minute warm up with the treadmill set to 1.6 km/h and the 
incline is set to 0%. The treadmill is subsequently set to 3.2 km/h and does not change for the 
remainder of the test. The incline increases by 3.5% every two minutes.  
1.2.4  N-terminal pro-Brain Natriuretic Peptide 
NT-proBNP is measured in plasma and is typically higher in patients with worse 
outcome. The addition of NT-proBNP measurement in an emergency department can improve 
the diagnostic accuracy of CHF compared to standard clinical judgment alone in patients 
presenting with dyspnea. In the COPERNICUS study, all-cause mortality and hospitalization 
were significantly higher in patients with higher plasma NT-proBNP levels than the median 
(Hartmann et al. 2004). The Australia/New Zealand Heart Failure trial demonstrated similar 
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findings (Richards et al. 2001). There is evidence to suggest NT-proBNP may be useful for 
titrating therapy of HF in the absence of worsening clinical symptoms. A trial randomly assigned 
278 patients to multidisciplinary care, NT-proBNP guided care, or usual care (Berger et al. 
2010). The NT-proBNP guided group had significantly reduced hospitalization days compared to 
the other two groups. Mortality at one year was significantly lower in the NT-proBNP guided 
care and multidisciplinary care compared to the usual care group. Another study with 364 
patients found similar results for patients age 60 to 75, but not over 75 years of age (Lainchbury 
et al. 2009).  
 
1.3  Cortisol 
Cortisol is a glucocorticoid produced by the zona fasciculata of the adrenal gland and is 
released in response to mental and physical stress. It is synthesized from de novo and circulating 
cholesterol. The first step in steroidogenesis involves the transport and loading of cholesterol into 
the mitochondria by the Steroidogenic Acute Regulartory Protein (stAR) followed by conversion 
to pregnenolone by the P450scc enzyme (Miller and Auchus 2011). Once pregnenolone is 
produced from cholesterol, it may be converted to progesterone or 17α-hydroxypregnenolone. 
For the biosynthesis of cortisol, both progesterone and 17α-hydroxypregnenolone is converted to 
17α-hydroxyprogesterone by P450c17 and 3β-hydroxysteroid dehydrogenase 2 (3βHSD2), 
respectively.  17α-hydroxyprogesterone is subsequently converted to 11-deoxycortisol by 
P450c21, which is converted to cortisol by P450c11β (Figure 2).    
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The release of cortisol is regulated by the hypothalamic-pituitary-adrenal (HPA) axis and 
acts to increase blood glucose and blood pressure, decrease inflammation and bone formation, 
and aid in fat metabolism. In response to stress, the paraventricular cells of the hypothalamus 
secretes corticotropin-releasing hormone into the hypophyseal portal system, triggering cells of 
the anterior pituitary gland to secrete adrenocorticotropic hormone into the bloodstream, which 
in turn triggers the adrenal cortex to release cortisol into the blood. Cortisol can down-regulate 
its own release through negative feedback on the pituitary and hypothalamus (Figure 3). It 
travels through the blood as both free cortisol (active) and bound to cortisol-binding globulin 
(inactive) (90%) (Dunn et al. 1981). Since free cortisol is lipophilic, it diffuses through the cell 
membrane and binds to its glucocorticoid receptor in the cytoplasm. This ligand-receptor 
complex subsequently enters the nucleus and regulates the transcription of target genes by 
binding to hormone response elements. In addition to the stress response, cortisol follows a 
diurnal profile – levels of cortisol peak in the morning (8 AM) and reach its lowest level at night 
(12 PM). The reason for this diurnal rhythm is not well understood. 
Cortisol is metabolized by the 11β-hydroxysteroid dehydrogenase system. Type 1 11β-
hydroxysteroid dehydrogenase (11β-HSD1) reduces biologically inert cortisone to biologically 
active cortisol, while type 2 11β-hydroxysteroid dehydrogenase (11β-HSD2) oxidizes cortisol to 
cortisone. Cortisol in high concentrations can cross-react and activate the mineralocorticoid 
receptor consequently leading to aldosterone-like effects such as hypokalemia, hypernatremia, 
and hypertension (Brunner et al. 2002). Since cortisone is less active than cortisol, the 11β-
hydroxysteroid dehydrogenase system is crucial to prevent overstimulation of the 
mineralocorticoid receptor. Clearance of cortisol involves the conversion of cortisol to 
dihydrocortisol in the liver. Dihydrocortisol is further metabolized to tetrahydrocortisol, which is 
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subsequently conjugated with glucoronic acid to form tetrahydrocortisol glucuronide before 
excretion in urine. 
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1.4  Testosterone 
Testosterone is an androgen primarily synthesized by Leydig cells in the testes of males 
and thecal cells in the ovaries of females. The biosynthesis of testosterone is similar to the 
biosynthesis of cortisol; however 17α-hydroxypregnenolone is converted to 
dehydroepiandrosterone (DHEA) by P450c17 (Miller and Auchus 2011). In Leydig cells, DHEA 
is converted to androstenedione by 3β-hydroxysteroid dehydrogenase type 2 (3βHSD2) and then 
to testosterone by 17β-hydroxysteroid dehydrogenase 3 (17βHSD3). DHEA can also be 
converted to androstenediol by 17βHSD3 and then to testosterone by 3βHSD2 (Figure 4). In 
thecal cells, androstenedione is converted to testosterone by AKR1C3 (minor pathway). The 
major pathway in thecal cells involves conversion of androstenedione to estrone by P450aro and 
subsequently estradiol by 17β-hydroxysteroid dehydrogenase 1 (17βHSD1) (Figure 5). 
Testosterone is cleared through the conversion of testosterone to androstenedione. 
Androstenedione is metabolized to androsterone and etiocholanolone, which are subsequently 
conjugated as sulfates and glucuronides for excretion in urine. Only a small portion of 
testosterone produced in the body is metabolized to testosterone glucuronide and is excreted as 
such in urine.  
The release of testosterone is regulated by the HPA axis and acts to increase bone density 
and muscle mass and in males, develop sperm. In response to low testosterone, the hypothalamus 
secretes gonadotropin-releasing hormone (GnRH) triggering the pituitary gland to secrete follicle 
stimulating hormone (FSH) and luteinizing hormone (LH) into the bloodstream. LH triggers the 
interstitial cells of the testes to synthesize testosterone, whereas FSH stimulates spermatogenesis 
in Sertoli cells of testes. The Sertoli cells secrete inhibin to down-regulate the release of FSH and 
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LH. Testosterone also down-regulates its own release through negative feedback on the pituitary 
and hypothalamus (Figure 5). It travels through the blood as both free testosterone and sex-
hormone binding globulin bound (25-50%). Like cortisol, free testosterone is lipophilic and 
diffuses through the cell membrane to bind to the androgen receptor in the cytoplasm. Free 
testosterone can also be reduced to 5α-dihydrotestosterone (DHT) in the cytoplasm by 5-alpha 
reductase. The ligand-receptor complex subsequently enters the nucleus and regulates the 
transcription of target genes by binding to hormone response elements.  
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Figure 4: Biosynthesis of testosterone in Leydig cells. 17βHSD3, 17β-hydroxysteroid 
dehydrogenase 3; DHEA, Dehydroepiandrosterone; 3βHSD2, 3β-hydroxysteroid 
dehydrogenase 2 (Adapted from Miller and Auchus 2011)  
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Estrone 
Estradiol 
P450aro 
Figure 5: Biosynthesis of testosterone in thecal cells. 17βHSD1, 17β-hydroxysteroid dehydrogenase 1; 
DHEA, Dehydroepiandrosterone; 3βHSD2, 3β-hydroxysteroid dehydrogenase 2 (Adapted from Miller and 
Auchus 2011)  
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1.5  Hair Physiology  
Hair fibers consist of several layers made up of the cuticle, cortex, and medulla (Figure 
7). The cuticle is the outermost layer of the hair shaft and acts as a protective barrier for the 
cortex and medulla. The cortex is located between the medulla and cuticle and contains melanin, 
giving the hair its colour. The innermost layer is the medulla. It is hypothesized that drugs and 
hormones enter the hair via the medulla through passive diffusion from the blood (Boumba et al. 
2006).  
Hair grows out from hair follicles. The hair growth cycle is composed of three stages: 
Anagen (growth phase), catagen (transition phase), and telogen (resting phase).  Anagen is the 
active growth phase of the hair. During this phase, cells at the root of the hair rapidly divide, 
subsequently elongating the hair strand. The anagen phase usually lasts around two to six years 
for human scalp hair before transitioning to the catagen phase (Boumba et al. 2006). In the 
catagen phase, blood supply is cut off from cells that produce new hair, consequently ending cell 
division (Boumba et al. 2006). This phase approximately lasts for two to three weeks before 
transitioning into the telogen phase. In the telogen phase, hair growth has stopped completely 
and germ cells below the root will produce a new hair strand to force the old strand out. This 
phase lasts for approximately 3 months. 
In general, individual hair strands are in different stages of the growth cycle. A healthy 
head consists of 80–90% of hair follicles in the anagen phase, 2% in the catagen phase and 10–
18% in the telogen phase (Harkey 1993). Scalp hair grows at a rate of 0.6 to 1.4 cm per month 
(Wennig et al. 2000).  
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1.6  Incorporation of compounds into hair  
Hair analysis has been demonstrated to accurately reflect exposure to drug abuse, 
environmental toxins and exogenous hormones (Raul et al., 2004; Villain et al., 2004). The 
incorporation of substances into hair still remains unclear; however, currently accepted models 
assume substances are incorporated into hair from passive diffusion from the blood, deep skin 
compartments, sweat, sebum, and the external environment (Figure 8). In general, lipophilic and 
basic molecules are more easily incorporated into the hair (Pragst et al. 2006). This is because 
Figure 7:  Hair structure (adapted from Boumba et al. 2006) 
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lipophilic substances can easily diffuse through membranes and the intracellular pH of 
melanocytes is more acidic than the pH of plasma.  
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 8:  Mechanisms of incorporation of compounds 
into hair (adapted from Pragst et al. 2004) 
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CHAPTER 2:  LITERATURE REVIEW AND STUDY RATIONALE 
2.1  Hair cortisol as a measure of stress  
One of the first studies to suggest that hair cortisol could be used as a biological marker 
of stress was done in macaque monkeys (Davenport et al. 2006). In this initial work, monkeys 
were relocated to a new home and hair cortisol levels were assessed pre- and post- move. Hair 
cortisol concentrations were about 60% higher post-move compared to pre-move, reflecting the 
stressful nature of moving to a new home. The hair cortisol levels returned to pre-move 
concentrations one year following the relocation.  
Over the past few years, we and other groups have conducted studies investigating the 
use of hair cortisol as a biological marker of chronic stress in humans. In 2007, our laboratory 
showed that infants who were hospitalized after birth had significantly higher hair cortisol 
concentrations compared to healthy term infants (Yamada et al. 2007). Infants in the neonatal 
intensive care unit showed that for each extra day on the ventilator, hair cortisol levels increased 
on average of 0.2 nmol/g. These results suggest that hair cortisol could potentially be a valid 
biological marker to assess chronic neonatal stress.  
In another study, our group showed that hair cortisol concentrations in pregnant women 
correlated with perceived stress as measured by the Perceived Stress Scale (PSS) (Kalra et al. 
2007). In brief, the PSS is a validated 10-item, psychological questionnaire to quantify perceived 
stress. In 2008, we demonstrated that hair cortisol levels were significantly elevated in patients 
with severe chronic pain compared to controls (Van Uum et al. 2008). Further, the PSS scale 
determined that subjective stress was greater in patients with chronic pain; however, correlation 
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between the PSS scale and hair cortisol levels in this study did not reach statistical significance 
(p = 0.08).   
A comparison between unemployed and employed individuals found that unemployed 
individuals had significantly higher hair cortisol concentrations (Dettenborn et al. 2010). These 
individuals also had increased levels of perceived stress; however, subjective measures of 
perceived stress did not correlate with hair cortisol. This study also discusses that the lack of 
association between cortisol levels and subjective measures of stress is not uncommon. There is 
evidence that suggests that associations between cortisol responses and self-reported stressors are 
mixed (Al’Absi et al. 1997; Buchananet al. 1999; Cohen et al. 2000; Oswald et al. 2004).  
 In 2010, Stalder et al. compared hair cortisol levels in abstinent alcoholics, alcoholics in 
acute withdrawal, and controls (Stalder et al. 2010). This group found that hair in alcoholics in 
acute withdrawal had four times the levels cortisol than those of abstinent alcoholics and 
controls. There were no differences in hair cortisol concentrations between the latter two groups.  
Another study investigating hair cortisol in young adults found that mean cortisol levels 
in 99 university students were significantly related to serious life events after multivariate 
analysis (Karlen et al. 2011). Of note, out of the four outliers with extremely high hair cortisol 
levels, this group managed to contact two students who reported serious psychological problems 
(anorexia and severe anxiety disorder). Investigators also demonstrated a very weak negative 
correlation between hair cortisol and perceived stress (r = -0.061, p < 0.05). 
Shift workers at a young age (less than 40 years) have also been shown to have higher 
levels of hair cortisol compared to day workers (Manenschijn et al. 2011). However, at an older 
age (greater than 40 years) there was no difference between shift and day workers. In this study, 
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hair cortisol levels were positively related to BMI, a finding in line with a recent study conducted 
by our group (Chan et al. submitted).  Manenschijn et al. suggest that the elevated cortisol 
concentrations and elevated BMI may contribute to the prevalence of metabolic syndrome and 
increased cardiovascular risk found in shift workers. 
Elevated hair cortisol levels has also been shown in endurance athletes (n = 304) 
compared to controls (n = 70) (Skoluda et al. 2012). Interestingly, a dose-response association 
was found between training volume and hair cortisol levels suggesting that repeated physical 
stress of intensive training and competitive races among endurance athletes is associated with 
elevated cortisol exposure over prolonged periods of time.   
 
2.2  Cortisol, Stress, and Cardiovascular Risk 
Numerous studies have been conducted associating salivary, urinary and serum cortisol 
with cardiovascular disease (CVD) risk and prognosis. Recent salivary cortisol studies have 
demonstrated an association between heightened cortisol reactivity to stress and incident 
hypertension and coronary artery calcification, suggesting increased HPA axis activation may 
influence the risk of CVD (Hamer et al. 2012a; Hamer et al. 2012b). The prognostic value of 
serum cortisol levels has also been evaluated in a large study of patients with chronic heart 
failure who were admitted to hospital due to various causes (Guder et al. 2007). This study 
demonstrated that higher serum levels of cortisol were independent predictors of increased 
mortality risk. Another recent study found that elevated plasma cortisol is associated with a 
greater prevalence of ischemic heart disease, independent of conventional risk factors (Reynolds 
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et al. 2010). Further, high urinary cortisol secretion strongly predicts cardiovascular death among 
persons both with and without pre-existing cardiovascular diseases (Vogelzangs et al. 2010).  
There is increasing evidence suggesting that cortisol may be involved directly in the 
pathological processes that lead to heart failure progression by activating the cardiac 
mineralocorticoid receptors similar to aldosterone (Arriza et al. 1987; Young et al. 2003). In both 
the Randomized Aldactone Evaluation Study (RALES) and the Eplerenone Post-AMI Heart 
Failure Efficacy and Survival study (EPHESUS), the beneficial effects of aldosterone blockade 
were observed despite normal plasma levels of aldosterone (Pitt et al. 1999; Pitt et al. 2001). This 
finding supports the concept that other ligands, such as cortisol, may activate the cardiac 
mineralocorticoid receptor in pathological conditions. Cortisol and aldosterone exhibit a similar 
affinity to the mineralocorticoid receptor, and free cortisol circulates at systemic concentrations 2 
orders of magnitude higher than aldosterone. This theory may suggest that patients with high 
cortisol levels may benefit more from mineralocorticoid receptor blockade. A recent study found 
in patients who were not treated with eplerenone, the total concentration of cortisol metabolites 
were associated with cardiac remodelling, while such a relation was not found  in patients treated 
with eplerenone (Weir et al. 2011). 
 
2.3  Testosterone and Cardiovascular Risk 
Similar to cortisol, testosterone studies have primarily used plasma as a matrix of 
measuring hormone levels. A study of 208 men with HF demonstrated that men with CHF have 
significantly reduced levels of testosterone (Jankowska et al. 2006). Furthermore, these 
deficiencies in testosterone have been associated with increased mortality. This study also 
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showed a significant stepwise decrease in the levels of both total testosterone and estimated free 
testosterone with worsening severity of CHF.  However, it is not known whether these 
deficiencies contributed to the severity of HF, were themselves the result of advanced HF, or 
whether they were markers of the severity of general chronic illness.  A recent study found that 
low testosterone predicted mortality from CVD, but not from other causes (Hyde et al. 2012).. 
Another group conducted a randomized, double-blind, placebo-controlled parallel trial of 
testosterone replacement therapy at physiological doses in 76 men with heart failure over 12 
months (Malkin et al. 2010). Exercise capacity and symptoms significantly improved at least one 
functional class with testosterone therapy compared with placebo, suggesting testosterone 
replacement therapy improves functional capacity and symptoms in men with moderately severe 
heart failure. A low testosterone level is associated with increased carotid intima-media thickness 
in men with low-grade inflammation (Soisson et al. 2012) and impaired endothelial function 
(Empen et al., 2012). Moreover, free testosterone was shown to be negatively correlated with 
Framingham risk score (a measure to estimate 10-year CVD risk), age, and BMI, but positively 
correlated with total cholesterol, LDL, and current smoking status (Chock et al. 2012). These 
associations suggest that low testosterone may suggest increased risk of CVD. Although an 
analysis of the Framingham population did not find an association between low testosterone and 
cardiovascular risk (Haring et al. 2013), a low serum testosterone was associated with increased 
risk of all-cause mortality (Haring et al. 2010).    
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2.4  Cortisol/Testosterone Ratio and Cardiovascular Risk 
In light of the association between high cortisol and increased cardiovascular risk factors 
and all-cause mortality, coupled with the association between low testosterone and all-cause 
mortality and possibly cardiovascular risk, the ratio of cortisol over testosterone might be 
particularly interesting. The clinical significance of the cortisol over testosterone ratio in serum 
has been demonstrated in the Caerphilly study, showing a strong positive correlation between 
this ratio and both the insulin resistance syndrome and incident ischemic heart disease (Smith et 
al. 2005). Additionally, the ratio of catabolic to anabolic steroid hormones, as measured by 
serum cortisol over dehydroepiandrosterone (DHEA) ratio, was higher in patients with CHF 
compared to controls (Anker et al. 1997). This metabolic shift toward catabolism in congestive 
heart failure (CHF) patients may cause progressive exercise intolerance and cardiac cachexia 
(Anker et al. 1997). Based on these data it is possible that the hair cortisol-testosterone ratio may 
be useful in population studies investigating the risk of metabolic syndrome and cardiovascular 
events. 
 
2.5  Knowledge Gap 
 To date, no studies have evaluated testosterone, measured in hair, and its association with 
CVD risk or prognosis. Only two studies have evaluated cortisol measured in hair to determine 
risk or prognosis of CVDs.  In 2010, our laboratory conducted a study on hair cortisol and the 
risk for acute myocardial infarction (AMI) in adult men and demonstrated that after controlling 
for all other risk factors, hair cortisol content remained the strongest predictor (Pereg et al. 2011). 
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A recent study demonstrated that higher hair cortisol levels were associated with a history of 
cardiovascular disease (Manenschijn et al. 2013). This study found that participants in the 
highest hair cortisol quartile had a 2.7 times increased risk of CVD. Importantly, this risk was 
similar to the effect of traditional cardiovascular risk factors such as hypertension, obesity, and 
dyslipidemia, suggesting that long-term elevated cortisol may also be an important risk factor. 
There were no associations between hair cortisol levels and non-cardiovascular diseases. There 
have been no studies to date that have examined hair cortisol and testosterone specifically in 
heart failure patients and their association with clinical outcomes. 
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CHAPTER 3:  HYPOTHESIS AND OBJECTIVES 
3.1  Primary Research Question 
 Does cortisol, testosterone, and their ratio (C/T), measured in hair, reflect heart failure 
status and prognosis? 
  
3.2  Hypothesis 
We hypothesized that high hair cortisol and low hair testosterone levels serve as 
biological markers of poor congestive heart failure prognosis.  
 
3.3  Objective 
To evaluate whether levels of hair cortisol and testosterone and the ratio of catabolic to 
anabolic steroid hormones, as measured by hair cortisol over testosterone (C/T) ratio, correlate 
with heart failure severity and prognosis in ambulatory patients with stable chronic systolic heart 
failure. 
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CHAPTER 4:  HAIR CORTISOL AND TESTOSTERONE IN 
PATIENTS WITH SYSTOLIC HEART FAILURE 
This section has been published: 
Pereg D*, Chan J*, Russell E, Berlin T, Mosseri M, Seabrook J, Van Uum S, and Koren G. Hair 
cortisol and testosterone as biological markers of systolic heart failure. 
Psychoneuroendocrinology. 38(12):2875-82, 2013  
* denotes co-first authors 
4.1  Introduction 
Progression of chronic congestive heart failure (CHF) is associated with activation of 
neuro-endocrine stress response systems including the hypothalamic-pituitary-adrenal axis that 
modulates the production and secretion of glucocorticoids including cortisol from the adrenal 
cortex (Güder et al., 2007; Brotman et al., 2007). The prognostic value of serum cortisol levels 
has been evaluated in a single large study of patients with chronic heart failure who were 
admitted to hospital due to various causes (Güder et al., 2007). This study demonstrated that 
higher serum levels of cortisol were independent predictors of increased mortality risk. However, 
it is possible that the single serum cortisol measurement may have been influenced by the 
physical stress due to the acute illness and/or the emotional stress associated with the admission 
itself. 
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Furthermore, deficiency of anabolic sex steroids is common among patients with CHF, 
affecting up to two thirds of patients (Moriyama et al., 2000; Jankowska et al., 2006).  Several 
studies have demonstrated that in patients with CHF a low serum testosterone is an independent 
predictor of mortality (Jankowska et al., 2006; Güder et al., 2010; Wehr et al., 2011). 
Furthermore, low serum testosterone has been correlated with other poor prognostic factors of 
heart failure including lower left ventricular ejection fraction (LVEF) (Jankowska et al., 2006), 
poor exercise capacity (Jankowska et al., 2009; Pastor-Pérez et al., 2011), high New York Heart 
Association (NYHA) class (Jankowska et al., 2006; Güder et al., 2010) and increased levels of 
NT-proBNP (Jankowska et al., 2006; Jankowska et al., 2009).  
 
Additionally, the ratio of catabolic to anabolic steroid hormones, as measured by serum 
cortisol over dehydroepiandrosterone (DHEA) ratio, was higher in patients with CHF compared 
to control patients (Anker et al., 1997). Further, the Caerphilly study found a positive linear 
association between the serum C/T ratio and future incident ischemic heart disease (Smith et al., 
2005).  While these studies were well designed, they all share the same limitation – the 
assessment of hormone levels was based on a single measurement. Given the level of intra-
individual variability in hormone levels, one serum sample may not be sufficient to characterize 
an individual's hormone levels (Smith et al., 2005; Brambilla et al., 2007; Brambilla et al., 2009).  
Cortisol and testosterone are typically measured in blood, urine, or saliva; however, these 
matrices only provide systemic hormone exposure over a period of 24 hours or less, are subject 
to diurnal variation (blood and saliva), can be invasive, and may require repeated measurements. 
The measurement of these hormones in scalp hair is a novel method allowing retrospective 
assessment of average cortisol and testosterone exposure over a period of several months using 
35 
 
only a single sample collection. Hair grows approximately 1 centimeter per month and therefore 
hair analysis reflects long-term endogenous production of cortisol and testosterone. For example, 
cortisol measurement from the most proximal 3 cm of hair represents the most recent 3 months 
of exposure (similar to the assessment of glucose levels using hemoglobin A1C). For the first 
time, this provides a reliable mode for measuring the accumulation of cortisol over time (Sauvé 
et al. 2007; Thomson et al., 2010). Several reports have demonstrated an association between 
high hair cortisol levels and various clinical conditions in both animal models and in humans 
(Yamada et al., 2007; Van Uum et al., 2008; Davenport et al., 2008; Stalder et al., 2010;  Gow et 
al., 2011; Pereg et al., 2011; Manenschijn et al., 2012). A recent study assessed the relation 
between hair cortisol and presence of metabolic syndrome in 1258 employees of a large 
company undergoing a voluntary health assessment (Stalder et al. 2013). Participants whose hair 
cortisol levels fell into the third and fourth quartile had an odds ratio for having metabolic 
syndrome of 1.71 and 2.42, respectively, as compared to the first quartile. Another recent study 
in community dwelling elderly patients demonstrated that higher hair cortisol levels were 
associated with a history of cardiovascular disease (Manenschijn et al. 2013). This study found 
that participants in the highest hair cortisol quartile had a 2.7 times increased risk of CVD 
compared to the lowest quartile. Importantly, this risk was similar to the effect of traditional 
cardiovascular risk factors such as hypertension, obesity, and dyslipidemia, suggesting that long-
term elevated cortisol may also be an important risk factor. However, this study cannot 
determine if increased hair cortisol also predicts future cardiovascular events. Furthermore, we 
have shown that testosterone levels in hair are lower in individuals with hypogonadism and 
normal in hypogonadal subjects on testosterone treatment (Thompson et al., 2009). The 
longitudinal assessment of cortisol and testosterone levels over time using the hair technique 
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may be more reliable than a single random serum sample for the assessment of chronic heart 
failure status and prognosis. 
 
Our objective was to evaluate whether levels of hair cortisol and testosterone and the 
ratio of catabolic to anabolic steroid hormones, as measured by hair cortisol over testosterone 
(C/T) ratio, correlate with heart failure severity and prognosis in ambulatory patients with stable 
chronic systolic heart failure. 
 
4.2  Methods 
The study was approved by the research ethics committee at the Meir Medical Center and 
written informed consent was obtained from each participant. The study was registered in the 
ClinicalTrials system (ID: NCT01139697). 
We included male patients above the age of 18 years with at least moderately reduced left 
ventricular systolic function defined as left ventricular ejection fraction (LVEF) ≤ 40%. All 
participants were routinely followed-up in either the outpatient cardiology clinic or cardiac 
rehabilitation center at the Meir Medical Center. Since we focused on patients with stable CHF, 
those with any hospital admission within the last 3 months prior to enrolment were excluded. 
Other exclusion criteria included any testosterone treatment, glucocorticosteroid treatment (either 
systemic or topical) within the last 6 months, diagnosis of Cushing's or Addison's disease, dyed 
hair, and morbid obesity (defined as body mass index >35 kg/m2).  Patients for whom a hair 
sample of at least 2 cm from vertex posterior could not be obtained were excluded for technical 
reasons.   
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All patients underwent a detailed standardized physical examination and clinical 
assessment including New York Heart Association (NYHA) class determination. Furthermore, 
hair samples and blood tests for basic chemistry, complete blood count, highly sensitive C-
reactive protein and NT-proBNP were drawn at enrolment. A treadmill exercise test was 
performed on all patients that were capable of completing a meaningful test. Following 
enrollment, we determined one year all-cause mortality and CHF-related hospitalizations data by 
collecting National Social Security records and through telephone follow-up. Patients with CHF 
were admitted to the hospital if CHF was the first and main diagnosis in the hospital discharge 
summary and if any of the following criteria were present: Respiratory distress or pulmonary 
edema, hypoxia, significant edema, syncope, or hypotension.  
End points 
The primary endpoints included the correlation of cortisol, testosterone, and the C/T ratio 
in hair with the New York Heart Association (NYHA) class, left ventricular ejection fraction 
LVEF, exercise capacity as measured by a treadmill exercise test and serum levels of NT-
proBNP. Secondary endpoints included all-cause mortality and CHF-related hospitalizations at 1 
year.  
Quantification of hair levels of cortisol and testosterone 
Scalp hair samples were obtained by a standard protocol established by the Motherisk 
Laboratory (Sauvé et al. 2007; Yamada et al. 2007; Thomson et al., 2010). The two most 
proximal centimeters of scalp hair, thought to represent two months of systemic hormone 
exposure in healthy individuals, were measured, cut, and weighed to a minimum of 10 mg in a 
glass scintillation vial. Each hair section was washed with 3 mL of isopropanol, allowed to dry, 
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and subsequently minced with surgical scissors in 1 mL of methanol. Scintillation vials were 
then incubated for 16 hours at 50 ºC on a plate shaker set to 100 rpm. Next, the methanol was 
removed into a glass test tube and evaporated under a stream of nitrogen gas at 50 ºC. Following 
evaporation, the hair extract was reconstituted in 250 µL of phosphate-buffered saline and 
vortexed for 30 seconds. Hair cortisol and hair testosterone concentrations were determined 
using different Alpco Diagnostics (Salem, NH, USA) salivary enzyme immunoassay kits 
(ELISA) specific for each hormone. For hair cortisol quantification, 50 µL of each sample was 
pipetted onto the plate in duplicate. For hair testosterone quantification, 100 µL of each sample 
was pipetted onto the plate in duplicate as per the manufacturer’s instruction.  
Hair samples with known cortisol and testosterone levels were used as positive controls. 
Phosphate-buffered saline was used as a negative control to assess non-specific binding and the 
values obtained were subtracted from all other values prior to interpretation to ensure accuracy of 
measurement. The intra- and inter-day coefficients of variation for the cortisol immune assay 
were determined using a standard sample of hair measured over several weeks and was 5.4% 
(n=4) and 7.6% (n=4), respectively. The limit of detection of the cortisol immunoassay kit was 
1.0 ng/ml (Alpco Diagnostics). Based on previous experience, cortisol levels above 1500 ng/g 
were excluded as they may possibly result from contamination or due to underlying Cushing 
(Thomson et al. 2010). For the testosterone immunoassay, the minimum required weight was 10 
mg for each sample. The intra- and inter-day coefficients of variation was 7.8% (n=4) and 9% 
(n=4), respectively. The limit of detection of the testosterone immunoassay kit was 1.0 pg/ml 
(Alpco Diagnostics). 
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Other laboratory measurements 
All other laboratory parameters, including basic chemistry (Boehringer Mannheim, 
Germany), and NT-proBNP (Roche diagnostics, Basel, Switzerland) were performed on fresh 
samples in the core laboratory facility of the Meir Medical Center. 
Echocardiographic assessment 
Complete Echo-Doppler study was performed on all participants within 1 month prior to 
enrollment. All studies were performed in our echocardiography laboratory according to a 
standardized protocol and were interpreted by the same echocardiographer.  
Treadmill exercise testing 
Stress test was symptom limited and patients were strongly advised not to use the 
handrails for support. All tests were conducted in the cardiac rehabilitation center at the Meir 
Medical Center. Either the modified Naughton or modified Bruce protocols (Working Group on 
Cardiac Rehabilitation & Exercise Physiology and Working Group on Heart Failure of the 
European Society of Cardiology, 2001) were used according to the attending cardiologist's 
assessment of the patient's functional capacity based on clinical evaluation and previous stress 
tests. 
Statistical Analysis 
 IMB SPSS Statistics version 20 was used to analyze data. Mean and standard deviation 
(SD) were used to describe normally distributed variables. All cortisol, testosterone and C/T ratio 
data are presented as median and range. Spearman’s rank correlation coefficient was used to 
assess the relationship between skewed continuous variables. The independent samples Kruskal-
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Wallis test was used to compare hair cortisol concentrations among the NYHA classes. 
Differences in hair cortisol and testosterone concentrations between hospitalized and non-
hospitalized patients were assessed using the Mann-Whitney U test. A univariate logistic 
regression was computed to obtain odds ratios for hair cortisol level and C/T ratio between 
patients who had a CHF-related hospitalization in the year following the inclusion in the study 
and those who did not. A p value < 0.05 was considered statistically significant.  
 
4.3  Results 
Participants 
A total of 52 patients fulfilled all the inclusion criteria; however 6 patients refused to 
participate. Two patients were excluded because of hair cortisol levels greater than 1500 ng/g, 
leaving 44 patients available for hair analysis.  This level was pre-determined to be an exclusion 
criterion on the basis of possible contamination from cortisol containing creams. After analysis 
of hair cortisol levels, there were 6 hair samples of insufficient weight for additional testosterone 
analysis. Therefore, 38 hair samples were available for hair testosterone analysis. Baseline 
characteristics of the 44 patients are presented in Table 1.  
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Table 1: Baseline characteristics of study participants. 
  Study population   
  (n=44)   
Age, years 69.8 (11.2)   
NYHA class    
    I/II/III, % 29/45/26   
Ischemic heart failure cause, % 84.2   
Echocardiographic features    
    LVEF, % 29.4 (7.7)   
    LVEDD, mm 61 (7.8)   
Comorbidities/risk factors    
   BMI, kg/m² 26.4 (3.9)   
   Hypercholesterolemia, % 79.2   
   Diabetes mellitus, % 29   
   Hypertension, % 68.4   
   Current cigarette smoking, % 18.4   
   Atrial fibrillation, % 23.7   
Medications    
    ACE inhibitors or ARB, % 89   
    β-Blockers, % 94.7   
    Spironolactone, % 36.8   
    Diuretics, % 57.9   
    Cardiac glycoside, % 13.2   
 
Devices  
  
    CRT, % 13.2   
    AICD, % 44.7   
Laboratory parameters  Reference Range  
    Hemoglobin, mg/dl 13.3 (1.5) 13.5 - 15.5  
    GFR-MDRD, ml/min/1.73m² 63.6 (23.3) >90  
    NT-proBNP, pg/ml 1976.8 (2957.2) 0 - 100  
    Hs-CRP, mg/dl 0.8 (1.0) 0 - 0.6  
Values are mean (SD) or %. LVEF indicates left ventricular ejection fraction; LVEDD, left 
ventricular end diastolic diameter; BMI, body mass index; ACE, angiotensin converting enzyme; 
ARB, angiotensin 2 receptor blocker; CRT, cardiac resynchronization therapy; AICD, automatic 
implantable cardioverter defibrillator; GFR-MDRD, glomerular filtration rate estimated by the 
Modification of Diet in Renal Disease formula; NT-proBNP, N-terminal pro-brain natriuretic 
peptide; Hs-CRP, highly sensitive C-reactive protein.  
 
 
42 
 
4.3.1 Cortisol 
Hair cortisol for the 44 CHF patients was 207 (117.7 - 1277.3) ng/g. Hair cortisol 
concentrations were positively correlated with NYHA class using Spearman’s rank (r=0.48, 
p=0.001). Furthermore, hair cortisol levels specified for the 3 NYHA functional classes are 
presented in Figure 9. Hair cortisol concentrations for NYHA class 1, 2, and 3 were 159.02 
(137.51 – 413.47) ng/g, 197.74 (117.68 – 1277.29) ng/g, and 363.12 (183.27 – 685.57) ng/g, 
respectively. Hair cortisol concentrations of NYHA stage 3 patients were significantly higher 
than levels in patients with stage 1 and stage 2. There was no significant difference in hair 
cortisol concentrations between NYHA stage 1 and stage 2 heart failure patients.   
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Figure 9: Hair cortisol content of CHF patients specified for NYHA stage.  Median (range) hair 
cortisol concentrations in stage 1, 2, and 3 heart failure patients were 159.02 (137.51 – 413.47) 
ng/g, 197.74 (117.68 – 1277.29) ng/g, and 363.12 (183.27 – 685.57) ng/g, respectively.  
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NYHA class correlated as well with NT-proBNP levels (r=0.54, p<0.01), LVEF (r=-0.64, 
p<0.01), and exercise capacity (r=-0.80, p<0.01). 
Of the 44 patients, 6 were not fit to perform a meaningful stress test due to non-cardiac 
causes (mainly orthopedic limitations), leaving 38 patients available for exercise capacity 
assessment. Hair cortisol concentrations were negatively correlated with treadmill stress test 
performance (r=-0.37, p<0.05) (Figure 10).  
 
Figure 10: Exercise capacity (metabolic equivalents) and hair cortisol concentrations (ng/g). 
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There was no statistically significant correlation between exercise capacity and either 
LVEF (r=0.13, p=0.44) or NT-proBNP (r=-0.07, p=0.70). We found no significant relationship 
between hair cortisol concentrations and LVEF (r=0.14, p=0.37) or NT-proBNP (r=0.19, 
p=0.22). 
During a 1-year follow-up, 25 (56.8%) patients had a CHF-related hospitalization. We 
found a non-significant trend toward higher hair cortisol levels in the hospitalized patients as 
compared to non-hospitalized patients; results were 183.61 (137.51 – 1277.39) ng/g and 278.60 
(117.28 – 1224.49) ng/g, respectively (p<0.08) (Figure 11A).   
The odds ratio for hair cortisol levels comparing patients with a CHF-related 
hospitalization to those without a hospitalization was also non-significant (OR=1.00, CI [0.99-
1.00]. Three patients died during the study period. This low number precluded any meaningful 
mortality analysis; however, hair cortisol concentrations for the patients who died were 187, 
372.72, and 411.17 ng/g. 
 
4.3.2 Testosterone 
The hair testosterone content in 38 patients was 5.17 (2.39 – 24.64) ng/g. There was no 
statistically significant association between hair testosterone and NYHA class (r=0.23, p=0.16), 
LVEF (r=-0.22, p=0.18), NT-proBNP (r=0.13, p=0.43), and exercise capacity (r=-0.07, p=0.63).   
Of the 38 patients, 17 had a CHF-related hospitalization at some point during the year 
after hair sampling. There was no difference in hair testosterone levels between hospitalized and 
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non-hospitalized patients; results were 5.12 (2.39 - 24.64) and 6.53 (2.40 - 15.98) ng/g, 
respectively (p=0.61) (Figure 11B).  
 
4.3.3 Cortisol over Testosterone Ratio 
The C/T ratio in 38 patients was 39.89 (12.98 – 173.73). There was no statistically 
significant correlation between the C/T ratio and NYHA class (r=0.17, p=0.30), LVEF (r=0.035, 
p=0.84), and NT-proBNP (r=0.13, p=0.45). The association between the C/T ratio and exercise 
capacity did not reach statistical significance, however we found a trend toward a negative 
association between C/T ratio and exercise capacity (r=-0.28, p=0.09).  
The C/T ratios for non-hospitalized and hospitalized patients were 37.53 (19.64 – 76.11) 
and 51.63 (12.97 – 173.68), respectively (p<0.05). A comparison between patients who had a 
CHF-related hospitalization in the year following the inclusion in the study and patients who did 
not have a CHF-related hospitalization revealed a higher C/T ratio in hospitalized patients (OR = 
1.04 (4%),CI [1.02 – 1.06], p<0.05) (Figure 11C). This odds ratio suggests that for every one-
unit increase in the C/T ratio, the odds of hospitalization increases 4%. 
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Figure 11: Median (range) hair cortisol concentrations for non-hospitalized and hospitalized 
patients (Panel A). Median (range) hair testosterone levels for non-hospitalized and hospitalized 
patients (Panel B). Median (range) C/T ratios of non-hospitalized and hospitalized patients 
(Panel C). 
A B 
C 
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4.4  Discussion 
The present study is the first to measure hair cortisol and testosterone as biomarkers for 
severity of CHF in men. We demonstrated that hair levels of cortisol correlated positively with 
NYHA class and negatively with exercise capacity.  These findings are of clinical significance 
since both the NYHA score and exercise capacity have been consistently included among the 
most powerful predictors of morbidity and mortality in patients with CHF (Pocock et al. 2006; 
O'Connor et al., 2012). We did not find any statistically significant association between hair 
testosterone and LVEF, NYHA class, exercise capacity, NT-proBNP, and one year CHF-related 
hospitalizations. Similarly, we did not find any statistically significant association between the 
C/T ratio and LVEF, NYHA class, NT-proBNP. On the other hand, patients who had a CHF-
related hospitalization had a significantly higher hair C/T ratio than patients who did not have at 
CHF-related hospitalization. We also demonstrated a tendency towards a negative association 
between C/T ratio and exercise capacity; however this did not reach statistical significance 
(p=0.09), possibly due to limited power.  
The association of high cortisol levels with adverse outcome of patients with CHF may 
have several possible explanations; however from this study, it is not entirely clear if CHF causes 
stress resulting in increased cortisol levels, or that the increased cortisol negatively affects 
cardiac function. First, cortisol is known to unfavorably affect classic cardiovascular risk factors 
including hypertension and insulin resistance which in turn can increase the cardiovascular risk 
(Brunner et al., 2002). Further, we have previously demonstrated hair cortisol was increased in 
patients admitted with acute myocardial infarction as compared to levels in control subjects 
(Pereg et al., 2011), indicating that systemic cortisol exposure in the two months before 
49 
 
admission was higher in patients who developed an acute myocardial infarct than in those in 
whom this did not happen. If cortisol indeed plays a causative role in the development of CHF, 
then it may be possible that CHF patients with high hair cortisol levels may benefit from a more 
intensive assessment and treatment of the existing conventional cardiovascular risk factors, and 
perhaps even from interventions that would reduce cortisol levels. Secondly, it is possible that 
the high cortisol level itself is not a direct cause for adverse outcome but rather a marker for high 
risk patients. 
The evidence is mixed with regard to testosterone levels and cardiovascular disease risk 
(Liu et al., 2003). Some studies have found an association between low testosterone and 
increased risk (Choong et al., 2010; Traish et al., 2011; Ullah et al., 2011), while others have not 
(Contoreggi et al., 1990; Arnlöv et al., 2006). A study of 208 men with heart failure found that 
deficiencies in serum testosterone were associated with increased mortality (Jankowska et al., 
2006). On the other hand, a prospective population-based study of 2084 participants without 
CVD at baseline, did not find an association between serum testosterone levels and incident 
CVD (Arnlöv et al., 2006). Moreover, an analysis of the Framingham population did not find an 
association between low testosterone and cardiovascular risk (Haring et al., 2013), similar to our 
findings with hair testosterone. In a study by Güder et al. (2010), free testosterone was found to 
be inversely associated with NYHA class and NT-proBNP. We did not find any association 
between hair testosterone and NYHA class or NT-proBNP. The lack of association between hair 
testosterone and serum NT-proBNP is not surprising as hair is a measurement of average long-
term hormone exposure, while measurements from serum are point measurements. As in the 
present study, Güder et al. also did not find an association between LVEF and free testosterone 
levels. Additionally, several studies have shown that testosterone supplementation improves 
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exercise capacity in patients with CHF (Pugh et al., 2004; Malkin et al., 2006; Caminiti et al., 
2009; Iellamo et al., 2010). We hypothesize that testosterone in hair may reflect free testosterone. 
In a recent study, we found a trend toward correlation between hair testosterone and the Free 
Androgen Index, while there was no such trend for total testosterone in serum (Chan et al. 
unpublished observations).  
To our knowledge, the present study and the Caerphilly study are the only two studies 
that prospectively investigate the C/T ratio in relation to CVD risk. In the Caerphilly study, a 
positive association was found between serum C/T ratio and incident ischemic heart disease and 
insulin-resistance during a mean of 16.5 years of follow-up (Smith et al., 2005).  In the present 
study, hair C/T ratio was able to predict CHF-related hospitalization status during the following 
one year (OR 1.04, p=0.04). This is a potentially important result suggesting that the hair C/T 
ratio may be superior to hair cortisol or testosterone alone at predicting morbidity and may be 
used as a mode for identifying high risk heart failure patients. 
Several limitations of this study warrant consideration.  Our analysis pertains only to 
male patients. Since CHF may be differentially affected based on gender, our results should be 
extrapolated to females with caution. Additionally, the size of our study was relatively small and 
patients were recruited in a single center. Therefore, it was not possible to control for clinical 
variables such comorbid conditions and medications. Nevertheless, the fact that despite a 
relatively small sample size hair cortisol levels correlated with both the NYHA class and the 
exercise capacity further supports the importance of measuring hair cortisol in heart failure. 
Additional studies with larger sample sizes are required to compare the reliability of hair cortisol 
and testosterone measurement in the assessment and risk stratification of CHF patients with that 
of the existing clinical and laboratory parameters. Moreover, this study did not use any 
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psychological stress questionnaires or collect any information on hair-related variables such as 
colour and frequency of hair washes. It also remains to be determined whether hair cortisol and 
testosterone levels are predictors of the main clinical endpoints in heart failure, such as sudden 
cardiac death, cardiovascular death and re-hospitalization rates. Furthermore, it is not known if 
changes in hair cortisol and testosterone over time predict or follow changes in clinical condition 
and/or treatment of CHF. Equally, we do not know if measurement of morning blood samples for 
cortisol and testosterone over time would have been congruent with the hair results. Finally, 
there are limitations to the measurements of hormones in hair. Obviously, it can only be done in 
patients with sufficient length of hair and is potentially subject to contamination by cortisol-
containing creams.  Additionally, the hair growth rate is assumed to be approximately 1 cm per 
month in healthy individuals. Our study population consisted of elderly patients with CHF, and it 
is not known if either the age and/or the impaired health may affect the hair growth rate, and thus 
the interpretation of timing of our results. Future studies that document the hair growth rate in 
relation to these and other factors are warranted. Furthermore, hair cortisol cannot be used to 
study dynamic impacts of morning awakening response of cortisol.  
In conclusion, our results suggest that higher hair cortisol levels correlate with the clinical 
severity of CHF as assessed by the NYHA score and treadmill exercise capacity. Going forward, 
our findings also highlight the potential importance of the C/T ratio measurement in hair, which 
may become useful as a research tool to assess other cardiovascular diseases such as myocardial 
infarctions. As this is the first study to use hair to measure cortisol and testosterone in patients 
with systolic heart failure, our results should be confirmed by future studies. 
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CHAPTER 5:  CONCLUSION 
 The objective of this research was to determine if hair cortisol, testosterone, and the C/T 
ratio reflect heart failure status and prognosis. This was the first study to measure hair cortisol 
and testosterone concentrations in CHF patients and determine any association of these 
hormones and their ratio with current CHF prognostic markers. We hypothesized that high hair 
cortisol and low hair testosterone levels serve as biological markers of poor congestive heart 
failure prognosis. 
Hair cortisol levels were positively correlated with NYHA class and negatively 
associated with exercise capacity. No significant relationships between hair cortisol levels and 
LVEF or NT-proBNP were found. We found a non-significant trend toward higher hair cortisol 
concentrations in patients who were hospitalized during the year following inclusion into the 
study. On the other hand, there were no associations between hair testosterone and any of the 
current HF prognostic markers. Likewise, the C/T ratio also was not related to any of the HF 
markers; however a negative trend between the C/T ratio and exercise capacity was found.  A 
comparison between patients who were hospitalized during the year following inclusion into the 
study and patients who were not hospitalized revealed a higher C/T ratio in patients who were 
hospitalized (OR=1.04). This odds ratio suggests that for every one-unit increase in the C/T ratio, 
the odds of hospitalization increases 4%. 
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Our results support our hypothesis that hair cortisol may serve as a biological marker of 
poor CHF prognosis. However, a limitation of using hair cortisol as a biological marker of CHF 
is that high hair cortisol levels are not specific to CHF. There are other reasons as to why an 
individual has elevated hair cortisol levels such as chronic pain and unemployment (Van Uum et 
al. 2008, Dettenborn et al. 2010). Our results regarding hair testosterone alone does not support 
our hypothesis that low testosterone serves as a biological marker of poor CHF prognosis. The 
results regarding the C/T ratio are particularly interesting and support our hypothesis. Additional 
studies are warranted to confirm our results.  
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CHAPTER 6:  STRENGTHS AND WEAKNESSES OF HAIR 
TESTING 
6.1  Strengths 
Cortisol and testosterone are typically measured in blood, urine, or saliva; however, these 
matrices only provide a window of systemic hormone exposure over a period of 24 hours or less, 
can be invasive, and may require repeated measurements. Scalp hair grows at a rate of 0.6 to 1.4 
cm per month (Wennig et al. 2000), allowing retrospective assessment of cortisol and 
testosterone exposure over a period of months and years with just a single sample collection. 
Many reviews of the literature have supported the validity of hair cortisol as a biological marker 
for chronic stress and human disease (Meyer et al. 2012, Russell et al. 2012, Gow et al. 2010). 
Hair collection is non-invasive, does not require health care workers, and can be conducted at 
any time of the day. Additionally, only a small amount of hair is required (minimum 10 mg of 
hair) for analysis. These features make hair collection well tolerated by participants.  
Another advantage of using hair as a matrix is that samples can be stored at room 
temperature and be sent by mail. We have demonstrated that mean hair cortisol levels from 
Peruvian mummies dating back to AD550 is similar to healthy volunteers today, suggesting 
cortisol’s stability over long periods of time (Webb et al. 2011).  Levels reflect average hormone 
levels over a period of months and years, whereas blood and saliva samples that reflect one 
moment in time, and urine that reflects levels during one day. Single time-point assessments 
using serum or urine can also be affected by the sampling itself and may provide a poor 
reflection of normal, long-term hormone levels and may be subject to diurnal variation (Stalder 
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et al. 2012). By contrast, hormone levels measured in hair are not affected by acute stress and 
hence may potentially be used even at or immediately after a major event, such as a myocardial 
infarction, which would cause acute changes in hormonal levels and thus not represent the 
hormonal milieu before the event (Pereg et al. 2011). 
 Measurements of hormones in hair, for the first time, provide an opportunity to provide a 
“timeline” of hormone exposure through segmental analysis. This is eloquently demonstrated by 
Manenschijn et al. in a study investigating if retrospective timelines of cortisol exposure could be 
created, using hair, in suspected cyclic Cushing’s patients and assessing if the timeline 
corresponds with symptomatic periods (Manenschijn et al. 2012).  They demonstrated that hair 
samples can provide a historical timeline that corresponds to the symptomatic periods in patients 
with cyclic Cushing’s (Figure 10). It is evident that hair could be a useful diagnostic tool for 
early detection such a condition, versus obtaining multiple, random serum, saliva, or urine 
samples. 
 
 
 
 
 
 
 
Figure 12:  Hair cortisol timeline of a patient with cyclic 
Cushing’s. (Adapted from Manenschijn et al. 2012)  
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6.2  Weaknesses 
There are several potential limitations to measurement of endogenous hormones in hair. 
Hair analysis is also unable to detect acute changes in hormone levels or the impact of brief 
stressors. Also, clinically relevant reference ranges for hormones measured in hair are yet to be 
established. Additionally, hair sampling is obviously limited to individuals who have sufficient 
hair at the vertex posterior and do not have cultural/religious objections to taking a hair sample. 
Studies investigating the effect of hair dying have shown that hair dying decreases cortisol 
concentrations compared to controls (Sauve et al. 2007; Manenschijn et al. 2011). A proposed 
mechanism for this phenomenon may be that the procedure for dying hair damages the hair shaft 
allowing cortisol to be leached out. Another mechanism is that dye may add extra weight to hair, 
thus erroneously decreasing hormone concentrations after correcting for weight.  No influence of 
natural hair colour has been reported to affect hormone concentrations in human hair (Sauve et 
al. 2007; Kirschbaum et al. 2009; Manenschijn et al. 2011). Finally, hair can be easily 
contaminated with the use of cortisol containing creams; therefore these individuals are typically 
excluded from studies measuring hair cortisol.    
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CHAPTER 7: FUTURE DIRECTIONS 
Hair is a unique tool that can be used to assess hormone exposures in the distant past 
(depending on the length of hair). The evidence is mixed as to whether or not hair cortisol 
concentrations are lower in the more distal ends of the hair shaft compared to the more proximal 
ends. Some studies have shown a declining pattern (Kirschbaum et al. 2009; Dettenborn et al. 
2010; Gao et al. 2010; Skoluda et al. 2011), whereas others have not (Thomson et al. 2010; 
Manenschijn et al. 2011). A possible mechanism for this decline may be that distal hair segments 
are more damaged due to UV light and frequent washing.  Indeed, Hamel et al. has demonstrated 
repeated washing of rhesus monkey hair with shampoo or water decreased hair cortisol levels 
(Hamel et al. 2011). However, human research has not found hair washing to effect hormone 
concentrations at least with respect to the proximal segments of hair (Manenschijn et al. 2011; 
Dettenborn et al. 2012). On the other hand, hair washing appears to lower hair cortisol content 
only in the distal segments (Dettenborn et al. 2012). These studies suggest that hair washing 
habits should be collected in future studies.  
It is generally accepted that hormones measured in hair reflect systemic hormone 
concentrations; however, there is some evidence that supports local cortisol production by hair 
follicles (Sharpley et al. 2010). To what extent local production of cortisol contributes to 
measurements remains an area to be investigated. 
Future studies should aim to take advantage of hair analysis’ ability to retrospectively 
obtain levels of hormones prior to an event, similar to our study on patients who had a recent 
myocardial infarction (Pereg et al. 2011). Indeed, our group has recently collected the hair of 
patients who had an ischemic stroke immediately after the ischemic event to determine if chronic 
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stress is a risk factor for strokes (Chan et al. in prep). Our preliminary results of this study show 
that hair cortisol levels of patients who had a recent ischemic stroke were not different compared 
to controls.  
More intervention studies would also be of interest. In 2010, our lab showed that hair 
cortisol concentrations decrease in patients with Cushing’s syndrome after surgical removal of an 
adrenal mass (Thomson et al. 2010). We have also demonstrated that hair testosterone levels of 
hypogonadal men receiving testosterone injections were significantly higher than those not 
receiving treatment (Thomson et al., 2009). Importantly, hair testosterone of men treated with 
testosterone was not significantly different from eugonadal men. These findings suggest that 
testosterone can be measured in the hair as a matrix and may be useful for monitoring 
testosterone therapy. Similarly, patients treated with hydrocortisone in patients with adrenal 
insufficiency showed higher hair cortisol concentrations compared to controls, suggesting these 
patients may be over-treated (Gow et al. 2010).  
It is certainly an exciting time for cortisol and testosterone detection in hair. The use of 
hair as a matrix to measure cortisol and testosterone provides a unique means of understanding 
the role of the long-term effects of these hormones.  
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